NASDAQ: ELOXEloxx Pharmaceuticals Inc Stock
$11.01+4.81 (+77.58%)
Updated Jun 9, 2026
ELOX Price
$11.01
Fair Value Price
N/A
Market Cap
$13.08M
52 Week Low
$0.00
52 Week High
$11.60
P/E
N/A
P/B
-1.72x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-2.12
Operating Cash Flow
N/A
Beta
-115.32
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ELOX Overview
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ELOX's potential to beat the market
- ELOX doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ELOX
RankedUnranked of 460
RankedUnranked of 460
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $229.19 | A | |
| $52.99 | A | |
| $15.78 | A |
Be the first to know about important ELOX news, forecast changes, insider trades & much more!
ELOX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ELOX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ELOX's short-term liabilities ($16.09M) exceed its short-term assets ($8.50M)
Short-term Liabilities Financials
ELOX's short-term assets ($8.50M) exceed its long-term liabilities ($0.00)
Long-term Liabilities Financials
ELOX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
There are 30 more ELOX due diligence checks available for Premium users.
Valuation
ELOX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0x
Industry
17.38x
Market
14.33x
ELOX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-1.72x
Industry
4.77x
ELOX's financial health
Profit margin
Revenue
$0.0
Net Income
-$3.8M
Profit Margin
0%
Assets to liabilities
Assets
$8.5M
Liabilities
$16.1M
Debt to equity
-2.12
ELOX's short-term liabilities ($16.09M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ELOX's short-term assets ($8.50M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ELOX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ELOX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.5M
Investing
$0.0
Financing
$7.0M
ELOX vs Biotech Stocks
Eloxx Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.